Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26558170 | 0.89 | TSHR (0.35) | ALDH1A1TSHRLMNACYP3A4NAAA | |
| SCHEMBL26558172 | 0.87 | TSHR (0.36) | ALDH1A1TSHRLMNACYP3A4 | |
| SCHEMBL26558138 | 0.85 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL26558178 | 0.85 | TSHR (0.32) | CNR1DAGLAALDH1A1TSHRLMNA | |
| SCHEMBL26558697 | 0.84 | ALDH1A1 (0.36) | ALDH1A1TSHRLMNACYP3A4MAPT | |
| SCHEMBL26558162 | 0.84 | CNR1 (0.33) | CNR1DAGLAALDH1A1TSHRLMNA | |
| SCHEMBL26558093 | 0.81 | — | — | |
| SCHEMBL26558181 | 0.79 | ALDH1A1 (0.37) | ALDH1A1TSHRLMNACYP3A4MAPT | |
| SCHEMBL26558114 | 0.79 | ALDH1A1 (0.35) | ALDH1A1TSHRLMNACYP3A4MAPT | |
| SCHEMBL26558184 | 0.79 | ALDH1A1 (0.32) | ALDH1A1TSHRLMNACYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | NUDT1, PNP, ATIC | CNR1 1210/4885DAGLA 3707/4885ALDH1A1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.